HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Targeted treatments for acute myeloid leukemia yield modest improvements, great hope
• Will targeted therapies become the mainstay of AML treatment?
• Research at ASH highlights progress, unmet needs in multiple myeloma
• Prostate cancer trials: Waiting for Godot Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• Risk-based approach must guide VTE prophylaxis for ambulatory patients with cancer Jai N. Patel, PharmD, BCOP, CPP
• Association of American Cancer Institutes launches initiative to advance CAR T-cell therapies
• ASCO policy statement targets financial barriers to clinical trial participation
• Ibrutinib alone, with rituximab improves PFS in chronic lymphocytic leukemia
• Stereotactic body radiation shows sustained local control in hepatocellular carcinoma
• Addition of alpelisib to fulvestrant significantly prolongs PFS in advanced PIK3CA-mutant breast cancer
• Patients with breast cancer who respond to neoadjuvant treatment may not need adjuvant chemotherapy
• Low-dose tamoxifen reduces recurrence of breast intraepithelial neoplasia
• Surgery choice affects quality of life among younger patients with breast cancer
• Oxybutynin shows promise for managing hot flashes among breast cancer survivors
• Axillary radiotherapy, lymph node surgery for early breast cancer confer comparable outcomes
• Accelerated partial breast irradiation noninferior to whole breast irradiation for invasive breast cancer
• Luspatercept effectively treats anemia in transfusion-dependent myelodysplastic syndrome
• Luspatercept reduces red blood cell transfusion burden in beta-thalassemia
• Improvement in acute promyelocytic leukemia survival driven by reduction in early mortality
• BCL2 mutation confers resistance to venetoclax in chronic lymphocytic leukemia
• Inpatient costs higher for young adults than children with acute lymphoblastic leukemia
• Consolidative transplant after CAR T-cell therapy may benefit certain patients with acute lymphoblastic leukemia
• Ibrutinib-based regimen superior to standard chemoimmunotherapy in chronic lymphocytic leukemia
• Tisagenlecleucel induces durable response among adults with pretreated diffuse large B-cell lymphoma
• Risk adjustment ‘negates benefit’ of stem cell transplant for acute myeloid leukemia
• Teenagers, women at higher risk for iron deficiency after blood donations
• Opioid use not associated with in-hospital mortality among patients with sickle cell disease
• Inexpensive sickle cell diagnostic tool shows perfect accuracy in Uganda
• Apixaban reduces recurrence of cancer-associated venous thromboembolism
• Red blood cell transfusion may not increase risk for thrombosis
• Researchers refine gene therapy approach for hemophilia A
• Smartphone app helps patients with cancer manage pain
• Adjuvant durvalumab safe, active for locally advanced esophageal adenocarcinoma
• Carfilzomib regimen extends multiple myeloma survival, regardless of renal impairment
• Financial incentives may influence oncologists’ practice patterns
• Obesity may increase risk for colorectal cancer among women
• No link between ADT, dementia among veterans with prostate cancer
• Study supports weekly low-dose cisplatin for advanced head and neck squamous cell carcinoma
• Levofloxacin lowers risk for bacteremia in pediatric acute leukemia
• Fatal toxic events possible, but rare, with immune checkpoint inhibitors
• Chemoradiotherapy safe, effective for older patients with limited-stage small cell lung cancer
• FDA grants breakthrough therapy status to SEG101 for pain crises in sickle cell disease
• FDA approves Cabometyx for treatment-experienced patients with HCC
• FDA grants fast track designation to vofatamab for bladder cancer subset
• FDA grants breakthrough therapy designation to zanubrutinib for mantle cell lymphoma
• FDA rejects sacituzumab govitecan for triple-negative breast cancer
• FDA approves Herzuma, biosimilar to Herceptin, for breast cancer subset
• FDA approves Keytruda for Merkel cell carcinoma
• FDA grants priority review to first-line Tecentriq-based regimen for small cell lung cancer
• FDA grants fast track designation to tumor-detecting intraoperative imaging agent
• FDA issues new framework for oncology drug development
• Bristol-Myers Squibb to acquire Celgene, Eli Lilly to acquire Loxo Oncology
• Fred Hutchinson bone marrow transplant program receives national recognition
• Fox Chase Cancer Center researcher receives American Cancer Society grant
• UCLA neurosurgeon receives award